Chimeric antigen receptor T‐cell therapies: Optimising the dose-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chimeric antigen receptor T‐cell therapies: Optimising the dose

Published:2020-03-24 Issue:9 Volume:86 Page:1678-1689
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Dasyam Nathaniel¹,George Philip¹²,Weinkove Robert¹²³^ORCID

Affiliation:

1. Cancer Immunotherapy Programme Malaghan Institute of Medical Research Wellington New Zealand

2. Wellington Blood & Cancer Centre, Capital & Coast DHB Wellington New Zealand

3. Department of Pathology & Molecular Medicine University of Otago Wellington Wellington New Zealand

Funder

Health Research Council of New Zealand

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14281

Reference117 articles.

1. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

2. Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts

3. Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

4. A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes

5. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An integrated perspective on measuring cytokines to inform CAR-T bioprocessing;Biotechnology Advances;2024-10

2. The method for assessing the specificity of developing CAR therapies;Biophysical Reports;2024-09

3. CAR T treatment beyond cancer: Hope for immunomodulatory therapy of non-cancerous diseases;Life Sciences;2024-05

4. Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells;EMBO Molecular Medicine;2024-02-14

5. CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review);Molecular Medicine Reports;2024-01-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3